CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

Impact · against what's priced in

MBX Biosciences has successfully aligned with the FDA on its Phase 3 trial design for canvuparatide, removing a significant layer of regulatory uncertainty. While the start date of Q3 2026 is distant, the confirmation of endpoints and the addition of EMA orphan drug designation provide a concrete roadmap for the lead candidate's path to market.

MBX+0.50

No priced-in read yet